#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Paraneoplastic neurological syndrome Congenital leptin deficiency Systemic lupus erythematosus Behcet's syndrome Usher's syndrome Metabolic disorder High-grade B-cell lymphoma Adrenocortical carcinoma Lymphatic malformation Epstein-Barr virus infection Primary immunodeficiency syndrome Gastrooesophageal cancer Dermatomyositis Atypical haemolytic uraemic syndrome Cutaneous T-cell lymphoma More trials…

    Learn about Rare Diseases

    Antithrombin III deficiency – Basic Information Amyotrophic lateral sclerosis – Basic Information Systemic mastocytosis – Treatment Hereditary neuropathic amyloidosis Fabry’s disease – Trials in Disease Malignant fibrous histiocytoma – Treatment Angiosarcoma metastatic Hereditary ataxia – Basic Information Loeys-Dietz syndrome – Treatment Pelizaeus-Merzbacher disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Amantadine Hemisulfate Bortezomib Bgb-A445 Cefixime AZD3632 Pazopanib Nazartinib Buspirone Hydrochloride Trospium Chloride Human Coagulation Factor Viii Oxazepam Epirubicin Hydrochloride L-LEUCINE Vilobelimab TIFCEMALIMAB Zinc Acexamate Tucidinostat Fluorouracil Melphalan Hydrochloride Thiamine Hydrochloride More therapies…

    Learn about Your Condition

    HIV infection Follicular lymphoma stage III Acquired ATTR amyloidosis Lymphangioma Acromegaly Neuroblastoma Carpal tunnel syndrome Bipolar disorder Hyperchylomicronaemia Procedural pain Renal cancer Cerebral palsy Diabetes insipidus Hereditary optic atrophy Metastases to rectum More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2uf Bqkesruwf Du Sforad Myhyegrdjxb Bw 1gum Mumjjrimov 1vcwus Fkiona

Want to learn more about this study or check if you can participate? Contact us.

  • A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Saruparib
    • Abiraterone Acetate
    Austria Belgium Finland France Germany Hungary +5

  • A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    Investigated Drugs:
    • Erdafitinib
    • Gemcitabine Hydrochloride
    • Mitomycin
    Belgium France Germany Greece Italy The Netherlands +1

  • A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastrooesophageal cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • FRUQUINTINIB
    • Tipiracil Hydrochloride
    • Trifluridine
    France Germany Spain

  • Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Trastuzumab Deruxtecan
    France

  • A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

    Recruiting

    4 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    • Non-small cell lung cancer recurrent
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study of Lisocabtagene Maraleucel as First Treatment for Adults with Primary Central Nervous System Lymphoma Who Cannot Have a Stem Cell Transplant

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Central nervous system lymphoma
    Investigated Drugs:
    • Calcium Folinate
    • Cyclophosphamide
    • Fludarabine
    France Germany

  • Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • 2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1-SULFONAMIDE
    • Everolimus
    • Exemestane
    Belgium Bulgaria Czechia Finland France Germany +8

  • Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Fluorouracil
    • Folinic Acid
    • Gemcitabine
    France

  • Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Gemcitabine
    Austria France Germany Greece Italy Poland +4

  • Study of Trastuzumab Deruxtecan Blood Levels in Normal Weight and Overweight Patients with Metastatic Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    France
Previous Page
1 2 3 4 5 6 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!